Pathology Presents: Potent Antibody-Based Conjugates for Cancer Therapy

This event has ended.

Speaker

Peter Senter, PhD
Vice President, Chemistry
Senior Distinguished Fellow
Seattle Genetics

Faculty Sponsor

Eddie Fox, PhD


Date & Time

February 17, 2016 at 4:30pm - 5:30pm

Location

Health Sciences Building, T-739

Calendar

Pathology Presents

Export
Add to Calendar 02/17/2016 04:30 PM 02/17/2016 05:30 PM America/Los_Angeles Pathology Presents: Potent Antibody-Based Conjugates for Cancer Therapy Pathology Presents: Potent Antibody-Based Conjugates for Cancer Therapy

Peter Senter, PhD
Vice President, Chemistry
Senior Distinguished Fellow
Seattle Genetics
Why Attend? Potent Antibody-Based Conjugates for Cancer Therapy: From Early Stage Research to a Clinically Approved Drug Monoclonal antibodies (mAbs) have played a major role in cancer medicine, with active drugs such as trastuzumab (Herceptin), cetuximab (Erbitux), bevacizumab (Avastin) and rituximab (Rituxan) in a wide range of therapeutic applications. The mechanisms of these agents involve such activities as direct signaling, interactions with Fc receptors on effector cells, and complement fixation. Several approaches have been explored to improve antibody-based therapies for cancer treatment by optimizing such activities and by conscripting their selectivity profiles for the delivery of high potency cytotoxic drugs. This latter area has advanced significantly in the past few years, with the approval of antibody drug conjugates such as Adcetris (brentuximab vedotin, SGN-35) for the treatment of relapsed Hodgkin lymphoma and anaplastic large cell lymphoma. This presentation will describe how Adcetris was discovered and developed, and will also overview how antibody drug conjugate technology for cancer therapy is being extended to include new antigen targets, new drugs, and new conditionally-labile linkers. hypersensitivity pneumonitis, advanced pulmonary Langerhans cell histiocytosis, end-stage pulmonary sarcoidosis, Erdheim-Chester disease, and Hermansky-Pudlak syndrome) will be presented, each with detailed clinical, radiologic, and histopathologic attributes, emphasizing similarities to and differences from IPF. 
Health Sciences Building, T-739 false MM/DD/YYYY

Description

Why Attend?

Potent Antibody-Based Conjugates for Cancer Therapy: From Early Stage Research to a Clinically Approved Drug

Monoclonal antibodies (mAbs) have played a major role in cancer medicine, with active drugs such as trastuzumab (Herceptin), cetuximab (Erbitux), bevacizumab (Avastin) and rituximab (Rituxan) in a wide range of therapeutic applications. The mechanisms of these agents involve such activities as direct signaling, interactions with Fc receptors on effector cells, and complement fixation. Several approaches have been explored to improve antibody-based therapies for cancer treatment by optimizing such activities and by conscripting their selectivity profiles for the delivery of high potency cytotoxic drugs. This latter area has advanced significantly in the past few years, with the approval of antibody drug conjugates such as Adcetris (brentuximab vedotin, SGN-35) for the treatment of relapsed Hodgkin lymphoma and anaplastic large cell lymphoma. This presentation will describe how Adcetris was discovered and developed, and will also overview how antibody drug conjugate technology for cancer therapy is being extended to include new antigen targets, new drugs, and new conditionally-labile linkers. hypersensitivity pneumonitis, advanced pulmonary Langerhans cell histiocytosis, end-stage pulmonary sarcoidosis, Erdheim-Chester disease, and Hermansky-Pudlak syndrome) will be presented, each with detailed clinical, radiologic, and histopathologic attributes, emphasizing similarities to and differences from IPF.